| D008297 |
Male |
|
Males |
|
| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D004621 |
Embolization, Therapeutic |
A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage. |
Embolotherapy,Therapeutic Embolization,Embolizations, Therapeutic,Embolotherapies,Therapeutic Embolizations |
|
| D004659 |
Enbucrilate |
A tissue adhesive that is applied as a monomer to moist tissue and polymerizes to form a bond. It is slowly biodegradable and used in all kinds of surgery, including dental. |
Butylcyanoacrylate,2-Cyanobutylacrylate,Butyl 2-Cyanacrylate,Chirurcoll,Enbucrilate, Homopolymer,Enbucrylate,Fimomed,Histacryl,Histoacryl,Histoacryl Blue,Histoacryl N-blau,Kanokonlit,Ligament-Fimomed,N-Butyl-2-Cyanoacrylate,N-Butyl-Cyanoacrylate,NBCA compound,Poly(Isobutyl Cyanoacrylate),Polybutyl Cyanoacrylate,Polyisobutyl Cyanoacrylate,Polyisobutylcyanoacrylate,2 Cyanobutylacrylate,2-Cyanobutylacrylates,Butyl 2 Cyanacrylate,Butyl 2-Cyanacrylates,Butylcyanoacrylates,Cyanoacrylate, Polybutyl,Cyanoacrylate, Polyisobutyl,Cyanoacrylates, Polybutyl,Cyanoacrylates, Polyisobutyl,Enbucrilates,Enbucrilates, Homopolymer,Enbucrylates,Histacryls,Histoacryl N blau,Histoacryls,N Butyl 2 Cyanoacrylate,N Butyl Cyanoacrylate,N-Butyl-2-Cyanoacrylates,N-Butyl-Cyanoacrylates,NBCA compounds,Polybutyl Cyanoacrylates,Polyisobutyl Cyanoacrylates,Polyisobutylcyanoacrylates |
|
| D006490 |
Hemostatics |
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. |
Antihemorrhagic,Hemostatic,Antihemorrhagics |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000328 |
Adult |
A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. |
Adults |
|
| D014689 |
Venous Insufficiency |
Impaired venous blood flow or venous return (venous stasis), usually caused by inadequate venous valves. Venous insufficiency often occurs in the legs, and is associated with EDEMA and sometimes with VENOUS STASIS ULCERS at the ankle. |
Insufficiencies, Venous,Insufficiency, Venous,Venous Insufficiencies |
|
| D016896 |
Treatment Outcome |
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. |
Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes |
|
| D055815 |
Young Adult |
A person between 19 and 24 years of age. |
Adult, Young,Adults, Young,Young Adults |
|
-transparent.png){kind=logo}
